If the word “hormones” makes you think “breast cancer,” you’re not being irrational you’re remembering a headline. Here’s what that headline actually said, and what the evidence shows now.

The 2002 headlines, in context

In 2002, the Women’s Health Initiative (WHI) a large study reported that menopausal hormone therapy increased the risks of breast cancer, heart disease, and stroke. What often gets left out is that most of the women in that study were over 60 and many years past menopause: not the group most likely to benefit from MHT in the first place. That context changed how experts think about timing.

Timing matters

Today, the emphasis is on when you start. The safest window is before age 60 or within ten years of your last period and MHT is meant to treat disruptive symptoms, not to be taken as a general preventive measure.

Started before 60 or within ten years of menopause, the risks look very different from the headlines that scared a generation.

The actual numbers

Combined systemic estrogen-progestin therapy slightly raises breast cancer risk about one extra case per 1,000 women per year after five years of use. Estrogen-only therapy (for women who’ve had a hysterectomy) appears to carry little in breast cancer risk in comparison to estrogen-progestin therapy.

The risks of stroke, or heart disease rise mainly when MHT is started after 60 or more than ten years past menopause; started earlier, those risks are much lower. How you take it matters too: oral estrogen affects clotting, as it goes through the liver after it is absorbed more than patches or gels, which is why transdermal options are often preferred for women with risk factors for blood clots or heart disease.

Vaginal estrogen is a different story

Low-dose vaginal (local) estrogen barely enters the bloodstream, so its systemic risk is very low to negligible. It has not been shown to increase the risk of breast cancer, heart disease, stroke, blood clots, or gallbladder problems and it’s considered safe even for many women who can’t take systemic hormones.

One thing MHT is not for

MHT is not recommended solely to prevent heart disease or cognitive decline in women who reach menopause at the usual age. Large randomized trials found it doesn’t reduce the risk of coronary heart disease, stroke, or dementia when it’s used only for prevention.

The honest summary: your age, your timing, and your personal history change the math. That’s a conversation to have with your provider, who can walk you through your own profile.

This article is general information, not medical advice. Menopausal hormone therapy is individualized any decision should be made with your own healthcare provider.